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A B S T R A C T
RAS proteins are critical regulators of signaling networks controlling diverse cellular functions such as cell
proliferation and survival and its mutation are among the most powerful oncogenic drivers in human cancers.
Despite intense efforts, direct RAS-targeting strategies remain elusive due to its “undruggable” nature. To that
end, bulk of the research efforts has been directed towards targeting upstream and/or downstream of RAS
signaling. However, the therapeutic efficacies of these treatments are limited in the long run due to the acquired
drug resistance in RAS-driven cancers. Interestingly, recent studies have uncovered a potential role of RAS in
redox-regulation as well as the interplay between ROS and RAS-associated signaling networks during process of
cancer initiation and progression. More specifically, these studies provide ample evidence to implicate RAS as a
redox-rheostat, manipulating ROS levels to provide a redox-milieu conducive for carcinogenesis. Importantly,
the understanding of RAS-ROS interplay could provide us with novel targetable vulnerabilities for designing
therapeutic strategies. In this review, we provide a brief summary of the advances in the field to illustrate the
dual role of RAS in redox-regulation and its implications in RAS signaling outcomes and also emerging redox-
based strategies to target RAS-driven cancers.
1. Introduction
The first observation of RAS oncogene was reported as early as 1964
when inoculation of murine leukemic virus isolated from leukemic rats
unintentionally induced sarcomas in newborn rodents [1]. This dis-
covery eventually paved the way for the identification of acute tumor-
inducing retrovirus and molecular characterization of its associated
viral gene that confers its oncogenic potency. Despite these seminal
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discoveries, enthusiasm in RAS oncogene only heightened upon the
discovery of its cellular homologues and its high prevalence of muta-
tions in cancer [2–6]. Research efforts spanning over half a century
eventually led to the discovery of numerous signaling pathways asso-
ciated with RAS activation. Not only do these signaling pathways
contribute to mitogen-independent growth of tumors, they are also
involved in acquisition of other established cancer hallmarks such as
cell survival, motility and angiogenesis as defined by Hanahan and
Weinberg [7].
Emerging alongside these discoveries, studies have also implicated
the diverse physiological functions of reactive oxygen species (ROS) in
cell survival and death signaling as well as their pathological relevance
to cancer initiation and progression, underscoring the potential cross-
talk between oncogenes and ROS in facilitating the acquisition of
cancer hallmarks [8–16]. To that end, recent studies provide over-
whelming evidence linking oncogenic signaling to an altered redox-
milieu that favors cell survival and promotes transformation and car-
cinogenesis. In a reciprocal manner, ROS are also able to regulate the
activities of oncoproteins. In this review, we attempt to summarize
experimental evidence demonstrating the interplay between oncogene
RAS and cellular redox status in the context of carcinogenesis as well as
present evidence, where relevant, of existing strategies and potential
therapeutic avenues targeting the RAS-ROS signaling network(s).
2. Intracellular generation of ROS
ROS are a heterogenous group of chemically reactive ions and
molecules derived from the reduction of molecular oxygen, O2, via
various cellular processes. The group encompasses both, oxygen-de-
rived radicals such as superoxide anion (O2•-) and hydroxyl radical
(HO•), and also non-radical species such as hydrogen peroxide (H2O2)
and hypochlorous acid (HOCl), which despite their non-radical prop-
erties, are powerful oxidizing agents. Beside its known deleterious ef-
fects, ROS are able to regulate protein activity through reversible oxi-
dative modification of redox-sensitive thiol/cysteine groups into
sulfenic, sulfinic, sulfonic or S-glutathionylated forms, thereby, altering
the function and activity of proteins. It is also worth mentioning that
Reactive Nitrogen Species (RNS), such as peroxynitrite (ONOO-), de-
rived from the reaction between nitric oxide (•NO) and O2•- can also
react directly with proteins and modify its activity and function.
However, due to its tendency to act in unison with ROS to induce cel-
lular effects, it is often loosely termed as ROS as well. Among all ROS,
superoxide anion and hydrogen peroxide remain the most extensively
studied. These two entities remain the most critical determinant of
oxidative stress and cell fate with specialized cellular antioxidant sys-
tems evolved to buffer and/or counteract their harmful effects.
The major source of intracellular ROS is the membrane bound
NADPH-oxidase complexes which consist of NOX family of enzymes
and its regulatory phox subunits and/or Rac GTPase (Fig. 1C). The NOX
family comprises seven isoforms (NOX1–5, DUOX1 and DUOX2), which
catalyzes NADPH-dependent one electron reduction of O2 to O2•-.
Among which, NOX1-NOX3 requires Rac GTPase for its activation
[17–19]. Similarly, NOX5, DUOX1 and DUOX2 activation requires
binding of calcium (Ca2+) to its calcium-binding domains and are
usually activated by upstream signaling pathways that increases cel-
lular Ca2+ levels [20,21]. Interestingly, NOX4 differs from the other
members of NOX family enzymes in that it is constitutively active and
produces predominantly H2O2 owing to its high affinity towards O2
[22]. DUOX enzymes, characterized by a defining N-terminal perox-
idase-like domain, also produces both O2•- and H2O2 [23]. However, the
ability for its peroxidase-like domain to catalyze conversion of O2•- to
H2O2 remains inconclusive [24]. Initially discovered as a membranous
protein required for ‘oxidative burst’ in phagocytes for antimicrobial
defense, NOX expression was found to be far more ubiquitous than
presumed [25]. Although O2•- production by NOX complexes are di-
rected towards extracellular space, studies have suggested that
extracellular O2•- can diffuse back into the cell via anion channels to
serve as intracellular messengers [26,27]. Importantly, the functional
relevance of NOX-produced ROS in promoting cancer cell survival and
proliferation has been demonstrated in various cancer cell types
[28–30].
The mitochondrial metabolic activity is another important source of
intracellular O2•-. During oxidative phosphorylation, adenosine tripho-
sphate (ATP) is generated as electrons shuttle through the mitochon-
drial electron transport chain (ETC), comprising of four multiprotein
complexes named I – IV, located on the inner mitochondrial membrane
(IMM). However, during electron shuttling, 1–2% of electrons in-
evitably leak out from the ETC leading to the reduction of O2 to O2•-
[31,32]. (Fig. 1A). Notably, mitochondrial complex I and III are the two
major sites within the ETC responsible for the by-production of O2•-
[33–37]. Besides the mitochondrial ETC, production of ROS by other
mitochondrial enzymes involved in the citric acid (TCA) cycle such as
pyruvate dehydrogenase and α-ketoglutarate dehydrogenase has been
reported, but the mechanism(s) remain unclear [38].
The endoplasmic reticulum (ER) is a site of critical redox-reactions
that assist in proper folding and maturation of proteins, resulting in the
generation of ROS [39]. The oxidative folding of proteins is catalyzed
by the oxidation of dithiol groups of targets by protein disulfide iso-
merase (PDI), during which, disulfide bond of PDI enzyme is reduced
(Fig. 1B). PDI is reverted to its oxidized from via ER oxidoreductase-1
(ERO1) and results in the reduction of terminal electron acceptor, O2 to
H2O2 [40,41]. Further substantiating the role of ER as a ROS-producing
organelle, NOX4 has been shown to localize to the ER and increase in
the in situ generation of ROS upon stress [42].
Last but not least, Nitric Oxide Synthases (NOSs) produces nitric
oxide, which is sometimes considered ROS due to the presence of an
oxygen moiety. Briefly, synthesis of nitric oxide by NOS involves single
electron reduction of O2 followed by its incorporation into guanidine
nitrogen of L-arginine to form •NO and L-citrulline [43]. The electron in
this reaction is derived from NADPH and transferred to the heme cat-
alytic center of NOS via a flavin mononucleotide (FMN)-prosthetic
group located on the C-terminal end of NOS [44]. Despite being a ra-
dical species with an unpaired electron, •NO exhibits low reactivity
towards biological molecules and is able diffuse across cell membrane
to neighboring cells, allowing it to serve as a signaling agent [45].
However, under high ambient O2•- concentrations, •NO can react readily
with O2•- to generate ONOO-, a strong oxidizing/nitrating agent [46].
ONOO- has been reported to damage DNA, proteins and lipids through
its oxidative/nitrative properties [47–51].
Other metabolic enzymes such as xanthine oxidase, cytochrome
P450, aldehyde oxidase have also been reported to produce ROS as by-
products [52–54]. However, they are not known to significantly influ-
ence disease initiation and/or progression of RAS-driven cancers. Thus,
they are beyond the scope of this review.
3. Cellular antioxidant defense systems
Uncontrolled increase in intracellular ROS could be detrimental to
cells and tissues, resulting in cell death and tissue damage. To that end,
cells employ various antioxidant enzymes and non-enzymatic systems
to maintain redox homeostasis and prevent oxidative stress-induced
injury/damage.
Nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2) is a major
antioxidant transcription factor and one of the first responders towards
increased oxidative stress [55]. Briefly, activation of Nrf2 involves the
dissociation of its negative regulator, Kelch-like ECH-associated protein
1 (Keap1), from Nrf2, allowing Nrf2 to translocate into the nucleus to
transcribe antioxidant genes [56,57]. The dissociation of Keap1 from
Nrf2 in response to oxidative stress involves the modification of redox-
sensing cysteine residues on Keap1 which presumably alters its struc-
ture and disrupts the Keap1/Nrf2 interaction [57,58]. Other mechan-
isms of Nrf2 activation has also been reported and reviewed in [59].
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The target genes of Nrf2 includes, but are not limited to, glutathione
peroxidase (GPx), peroxiredoxin (Prx), thioredoxin (Trx), glutathione
disulfide reductase (GSR), thioredoxin reductase (TrxR) [60–66]. The
antioxidant function of these proteins would be elaborated later within
this section.
Superoxide produced via cellular processes is removed through a
series of reactions involving dismutation of O2•- to H2O2 by the action of
superoxide dismutase (SOD) enzymes (Fig. 1D). Three SOD isozymes
are characterized to date, namely CuZnSOD (SOD1), MnSOD (SOD2)
and ECSOD (SOD3) which exhibit differences in their structure, spatial
distribution and metal-containing catalytic center. Catalytic activity of
SOD1, found primarily in the cytosol and mitochondrial intermembrane
space, is driven by copper (II) ion (Cu2+) and zinc (II) ion (Zn2+) [67].
In contrast, catalytic activity of SOD2 is driven by manganese (III) ion
(Mn3+) and is found primarily in the mitochondrial matrix. SOD3 has a
similar structure to SOD1 with an additional secretory sequence that
allows its secretion into extracellular space where it converts extra-
cellular O2•- to H2O2 [68]. Like O2•-, extracellular H2O2 can diffuse back
across the plasma membrane via aquaporin channels to carry out its
intracellular signaling functions [69].
Within the cell, H2O2 can be further detoxified via a number of
antioxidant defense systems. Catalase catalyzes the decomposition of
H2O2 to H2O and O2. Besides catalase, H2O2 can also be reduced to H2O
by GPx. The reduction of H2O2 to H2O by GPx involves the oxidation of
glutathione to glutathione disulfide (GSH to GSSH), which is
subsequently recycled to form GSH via GSR [70,71]. In addition to
GSH, another major antioxidant enzyme, Prx, scavenges H2O2, per-
oxides and peroxynitrite (ONOO-) through oxidation of its own redox-
active thiol groups. Oxidized Prx (Prxoxd) then uses reduced Trx (Trxred)
as an electron donor to restore its reducing capacity. Trxoxd is, in turn,
regenerated through reduction by Trx reductase. Central to redox-cy-
cling of the antioxidant defense system is cofactor NADPH which serve
as an electron donor for the reduction of GSSG and Trx via GSR and Trx
reductase, respectively [72].
As these antioxidants are crucial in maintenance of intracellular
redox-homeostasis, compromised antioxidant function coupled with
aberrant ROS generation results in an altered redox milieu (pro-oxidant
state), associated with carcinogenesis and its progression.
4. Redox Paradox in cancer cell fate
Due to the ability to spontaneously induce oxidative damage to
biological systems and involvement in the etiology of various patho-
logical states, ROS have historically been regarded as noxious mole-
cules. Despite these overstated deleterious effects, mounting evidence
has challenged the dogmatic view of ROS as noxious molecules and
revealed an essential, yet complex signaling role for ROS under both
normal and pathophysiological states. Indeed, ROS have been im-
plicated in myriad of cellular processes and signaling networks in-
cluding those associated with the various phases of carcinogenesis:
Fig. 1. Cellular sources of ROS. ROS are inevitable byproduct of cellular metabolism and are generated in various cellular compartments. (A) The mitochondrial ETC
generates O2•- as electrons are shuttled from complexes I and II to III and IV through a series of redox-reactions. Electrons are derived from the oxidation of NADH to
NAD+ at complex I and oxidation of FADH2 to FAD+ at complex II. The inevitable leakage of electrons causes the reduction of O2 to O2•-. Complex I and III are major
sites of O2•-production within the ETC. (B) ER is another site of ROS production. PDI catalyzes disulfide bond formation, required for the maturation of its protein
substrate. During which, PDI reduces its own disulfide bond to two dithiol groups. The restoration of PDI activity involves oxidation of dithiol group by ERO1 with
FADH2 as a cofactor and results in reduction of terminal electron acceptor, O2 to H2O2. (C) NOX complexes (NOX2 depicted in figure) consists 6 subunits. Namely,
gp91phox, p22phox,p47phox, p40phox, p67phox and Rac. Electrons released from the oxidation of NADPH reduces extracellular O2 to O2•-. NOX4 and DUOX produces
both O2•- and H2O2. (D) O2•- are dismutated into H2O2 by SOD enzymes. H2O2 is further decomposed into H2O and O2 by catalase, GSH or Prx. There are other sources
of ROS stated in-text that were not depicted within this figure.
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initiation, promotion and progression. These effects are a result of the
redox-regulation of cell growth and survival mechanisms, such as in-
hibition of cell death (apoptosis resistance) and/or activation of pro-
liferative pathways or conversely excessive DNA damage and cell ex-
ecution. The latter effects of ROS are associated with excessive ROS
accumulation that results in extensive macromolecule damage such as
lipid peroxidation, protein oxidation and DNA damage, triggering cell
death/growth arrest pathways that facilitate the removal of cells with
irreparable lesions. An example is the p53 tumor suppressor, which is
critically involved in the induction of apoptosis or growth arrest in
response to oxidative stress-induced DNA damage [73,74]. Similarly,
increase in intracellular ROS can also induce apoptosis via sustained
activation of c-Jun N-terminal Kinase (JNK) [75,76], possibly stemming
from the ROS-dependent inactivation of mitogen-activated protein ki-
nase (MAPK) phosphatase (MKP) that dephosphorylates/inactivates
JNK. The inactivation of MKP is a result of catalytic cysteine oxidation
to sulfenic acid by H2O2 [77]. In another study, ROS has also been
implicated in the activation of apoptosis signal-regulating kinase-1
(ASK1) which induces apoptosis through downstream activation of
JNK/p38 MAPK [78].
In addition to apoptosis, ROS has also been demonstrated to be a
robust activator of other forms of cell death. For instance, mutant RAS-
selective small molecule compound, erastin, increases cytosolic and
lipid ROS production via inhibition of cysteine uptake through cy-
steine/glutamate antiporter (system Xc-) required for cysteine-depen-
dent GSH synthesis, compromising antioxidant defense, ultimately re-
sulting in an iron-dependent, oxidative cell death known as ferrotoposis
[79]. A number of studies has also implicated ROS in mediating ne-
crotopsis, a programmed form of necrotic cell death. Notably, combi-
nation treatment of Smac-mimetic BV6 and tumor necrosis factor-α
(TNF-α) induces ROS-dependent assembly of receptor-interacting
serine/threonine-kinase 1(RIPK1)/RIPK3 necrosome which drives ne-
croptosis via phosphorylation and activation of mixed lineage kinase
domain like pseudokinase (MLKL) [80]. Interestingly, deficiencies in
critical TNF-α-induced necroptosis signaling proteins such as TNFR-
associated factor (TRAF)2, Fas-associated death domain (FADD) and
RIPK3 ameliorate ROS production and reduce cell death, indicating the
importance of a ROS amplification loop in mediating this unique form
of cell death [80,81].
Contrary to its death-inducing property, a substantial amount of
evidence has also revealed that ROS, within physiological levels,
function as secondary messengers. This signaling property of ROS is
often mediated by the reversible oxidation of cysteine thiol groups
within proteins, altering their function and activity, thereby regulating
the respective signaling pathways the proteins are involved in [82–86].
Notably, H2O2 inactivates tumor suppressor phosphatase and tensin
homolog (PTEN), a negative regulator of phospoinositide-3-kinase/
protein kinase B (PI3K/AKT) signaling pathway via reversible oxidation
of the cysteine residues, resulting in increased PI3K/AKT signaling. The
inactivating oxidative modification can be reversed by Trx-mediated
reduction of PTEN, thereby restoring its phosphatase activity and
downregulation of PI3K/AKT signaling [84]. Similarly, O2•- is able to
reversibly inactivate PTEN via oxidative modification, resulting in in-
creased phosphoinositol-(3,4,5)-triphosphate levels, thereby increasing
PI3K/AKT signaling [85]. Further supporting the role of oxidants in
signal transduction, H2O2 has also been implicated in the reversible
oxidation and inhibition of SH2 domain containing protein tyrosine
phosphatase (PTP), resulting in burst of protein tyrosine kinases ac-
tivity, a principle mode of mitogenic signal transduction [86].
From the standpoint of carcinogenesis, the biphasic functions of
ROS can be difficult to grasp given its conflicting role in cancer. On the
one hand, cancer cells often display higher levels of oxidative stress
compared to normal cells due to oncogenic stimulation and altered
metabolism, which are important for cancer initiation and progression
[87–90]. On the other hand, ROS can also induce multiple tumor sup-
pressive mechanisms such as activation of p53 [73,77,91]. In fact,
augmentation of oxidative stress is the basis of many chemotherapeutic
and radiotherapeutic agents’ mechanism of action [92–94]. How then,
do cancer cells reconcile with the conflicting effects of ROS on cell fate de-
termination? Underpinning these contradictory responses seem to be a
concentration-dependent pathology, wherein a threshold exists to dis-
tinguish between the signaling functions and toxic effects of ROS
(Fig. 2). Hence, while leveraging on the beneficial effects of ROS to
promote its own survival and proliferation, a cancer cell must also ac-
tively keep its ROS levels in check by enhancing its own antioxidative
capacity to prevent cell death. Herein, we will focus on how RAS, a
potent oncogene, promote and maintain the cancer phenotype in a
redox-regulated manner.
5. Rising ROS levels float RAS signaling
RAS are 21 kDa small GTPase that regulate diverse cellular
Fig. 2. Biphasic effects of ROS within RAS
signaling. ROS evoke a variety of cell responses
based on its concentration, spatial and tem-
poral distribution, and cell type. Generally,
moderate increase in ROS levels promotes cell
proliferation and survival while extremely high
levels of ROS promotes DNA damage, growth
arrest, senescence and cell death. Oncogenic
RAS signaling has been shown to promote cell
proliferation and survival associated with ROS
production. Accompanied by the increase in
ROS production, RAS signaling also induces
activation of antioxidant response to buffer
ROS levels from reaching toxic levels. Potential
therapeutics may consider leveraging on RAS
signaling to augment ROS levels.
C.H.J. Foo, S. Pervaiz Redox Biology xxx (xxxx) xxxx
4
processes such as cell proliferation, survival and metabolic repro-
gramming. In human, three subfamily RAS genes – NRAS, HRAS and
KRAS - encode for 4 highly homologous RAS isoforms, NRAS, HRAS and
splice variants KRAS4a and KRAS4b. Localized on the cell plasma
membrane, RAS proteins serve as critical signaling nodes which trans-
duce extracellular signals from membrane receptors to a complex net-
work of intracellular effector pathways. This is achieved by transitions
between its active guanosine triphosphate (GTP)- bound conformation
upon GDP loading and inactive guanosine diphosphate (GDP)-bound
conformation upon GTP hydrolysis. Under physiological conditions,
tandem switching between “active” and “inactive” conformations is
modulated by GTP exchange factors (GEFs) and GTPase-activating
proteins (GAPs), ensuring signal transduction to be transient and effi-
ciently controlled. Hence, RAS are known to be effective “molecular-
switches”. Molecular analysis of RAS-driven tumors has identified RAS
mutational hot spots in codons 12, 13 and 61 at varying frequencies
[95]. These mutations disrupt GTP hydrolytic capacity of RAS GTPase
resulting in incessant proliferative and survival signaling through sti-
mulation of downstream effectors such as RAF/MEK/MAPK, PI3K/
AKT/mTOR and RalGEF/Ral pathways.
Apart from receptor-mediated and mutational activation, increased
ROS levels have also been linked to the activation of RAS. Notably,
ROS-induced activation of RAS was first observed in human T cells
where increased •NO levels increased RAS-GDP dissociation, allowing
for subsequent GTP binding and activation [96]. The molecular target
of nitric oxide-mediated RAS activation was later identified to be the
highly conserved NKXD (asparagine-lysine-X-aspartate) nucleotide-
binding motif of RAS superfamily where Cys118 is the variable X residue
in HRAS, NRAS and KRAS [97,98]. Presumed to be mediated by S-ni-
trosylation of Cys118, the guanine nucleotide exchange (GNE) of RAS is
facilitated via the formation of RAS-thiyl intermediate (RAS-S•) during
the process of S-nitrosylation of the thiol group of Cys118 by nitrogen
dioxide (•NO2), a reaction product of •NO and O2, rather than the S-
nitrosylated end-product [99–101]. Similarly, O2•- and H2O2 in the
presence of transition metals such as copper (Cu2+) and iron (Fe2+),
and peroxynitrite (ONOO-) have also been reported to facilitate RAS-
GDP dissociation and GTP exchange [102,103]. RAS-S• intermediate
may also be formed during S-glutathiolation of RAS Cys118 residue,
stimulating RAS activation through GNE [104]. However, this mod-
ification prevents Cys118 from engaging in further radical-based reac-
tions [104]. Site-directed mutagenesis of Cys118 to serine impedes
carcinogen-induced lung carcinogenesis in mice. Interestingly, duo-site
mutated KRASC118S, G13D displayed decreased sensitivity towards epi-
dermal growth factor (EGF) stimulation compared to single-site mu-
tated KRASG13D, suggesting synergism between ROS and oncogenic RAS
mutations in promoting carcinogenesis. Taken together, these studies
provide evidence of ROS-dependent activation of RAS signaling in
promoting carcinogenesis.
6. RAS: A master redox-rheostat in cell fate determination
6.1. Pro-oxidant activity of RAS
Besides the amenability of RAS structure/activity towards oxidative
modifications, RAS activation is also a strong inducer of cellular ROS
production associated with tumor-promoting effects of RAS. In that
regard, many critical intracellular pro-oncogenic networks that are
modulated by mutant RAS signaling such as autophagy, NF-κB and
MAPK activation, PI3K/AKT/mTOR and hypoxia signaling appear to be
highly intertwined with cellular redox metabolism. Mutant KRAS was
shown to promote oxidative stress in pancreatic cancer by induction of
miR-155 through NF-κB and MAPK pathway, resulting in down-
regulation of transcription factor, FOXO3A, which transcribes for an-
tioxidant genes, SOD2 and catalase [105]. Besides transcriptional
downregulation of ROS-scavenging enzymes, RAS has also been shown
to induce mitochondrial O2•- production from complex I and III of the
ETC required for activation of proliferative and survival signaling, al-
though a consensus has not been reached as to whether this is due to an
increase in mitochondrial dysfunction or mitochondrial metabolism
[106–108]. The conflicting reports may be due to differences in cell
models used [106–108]. It is also worth mentioning that AKT, a
downstream effector of RAS, can further increase oxidative stress by
increasing respiratory capacity and/or suppressing FOXO3A activity
[109–111], conceivably resulting in a ROS amplification loop to favor a
pro-oxidant milieu for carcinogenesis. Supporting the role of ROS in
promoting cancer cell proliferation, null-mutation of Prx1 greatly en-
hanced proliferation of non-small cell lung cancer (NSCLC) via ROS-
dependent stimulation of ERK/CyclinD1 pathway in KRAS-driven lung
carcinogenesis, suggesting a tumor suppressor role of the antioxidant
activity of Prx1 [112]. Similarly, oncogenic RAS was observed to inhibit
transcription of sestrin family genes SESN1 and SESN3, resulting in
increased intracellular ROS levels [91].
Perhaps the most convincing evidence linking ROS to RAS-induced
transformation and cancer progression is its ability to directly induce
O2•- production via the intermediary activation of Rac1 GTPase [113], a
critical component of NOX complexes [25,114]. O2•- production via
Rac1 has been shown to be an important mediator of mitogenic sig-
naling and is required for malignant transformation and cancer pro-
gression in various RAS-driven cancer models [108,115–119]. More-
over, RAS activation in colorectal carcinoma strongly correlates with
NOX1 expression and its expression has been linked to activation of
MAPK [30,89,120]. Apart from NOX, our group has demonstrated that
Rac1 localized to the mitochondria where it interacts with Bcl-2 and
increases mitochondrial O2•- production, promoting survival [121].
Besides the aforementioned studies demonstrating RAS as an in-
ducer of ROS production which subsequently promotes mitogenic and
survival signaling, there exists a preponderance of evidence attesting
ROS production as an integral component of RAS-induced transforma-
tion. In pancreatic cancer, where frequency of KRAS mutations are up
to 90%, constitutive RAS activation was shown to induce cellular ROS
production via NOX4 to promote cancer progression in a Rac1-depen-
dent manner [122]. RAS-induced ROS production via NOX4 also pro-
motes accumulation of DNA damage which may result in the acquisi-
tion of additional oncogenic hallmarks or oncogene-induced senescence
if DNA-damage response is activated [122,123]. Previously thought to
be a tumor suppressive mechanism to arrest cells at risk of malignant
transformation, mounting evidence suggests that senescent cells can
evoke pro-tumorigenic changes in tumor microenvironment through
acquisition of senescence-associated secretory phenotype (SASP) (re-
viewed by Coppé) [124].
Although oncogenic RAS promotes carcinogenesis through incessant
proliferative and survival signaling, it has become clear over the years
that oncogenic RAS also requires other mechanisms to sustain tumor
progression. One of these critical mechanisms tied to RAS-driven
transformation and redox-signaling is autophagy, a “self-eating” me-
chanism through which organelles, part of cytoplasm or proteins are
digested to sustain metabolic needs or prevent accumulation of da-
maged/unwanted proteins and organelles [87,125–128]. Indeed, au-
tophagy manifests in KRAS-driven malignant transformation of
MCF10A breast epithelial cells through ROS-dependent activation of
stress kinase, JNK, inducing upregulation of critical autophagy-related
genes Atg5 and Atg7. Suppression of autophagy via genetic knockdown
of autophagy-related (Atg) genes and ROS scavenging in this model,
attenuated malignant transformation [126]. In agreement with this
study, our group has shown that a small molecule compound, 1,3-di-
butyl-2-thiooxo-imidazolidine-4,5-dione (C1), was able to trigger be-
clin-1 independent autophagy in various cancer cell lines and primary
cells from lymphoma patients through ROS-dependent activation of
MAPK, ERK and JNK [12]. It has also been reported that autophagy is
an important mechanism for sustaining glycolysis during RAS-driven
tumorigenesis and deficiencies in autophagy resulted in lower glyco-
lytic flux and reduction in cell proliferation, indicating that autophagy
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may be required to maintain ATP homeostasis during nutrient depri-
vation [128]. Interestingly, suppression of autophagy in RAS-driven
NSCLC with p53 loss disrupts lipid metabolism and changes the fate of
adenoma and carcinoma to benign oncocytoma [129]. Collectively,
these studies testify the importance of autophagy in supporting meta-
bolic reprograming during RAS-driven transformation and cancer pro-
gression, and changes in cellular-redox status mediated by oncoprotein
RAS is an important mediator of these changes.
6.2. Anti-oxidant activity of RAS
While RAS promotes cellular transformation and tumor progression
through induction of ROS, persistent ROS production as a result of RAS
signaling can trigger growth arrest or cell death mechanisms. To
overcome the deleterious effects of ROS, RAS must rely on failsafe
mechanisms to neutralize and/or reduce ROS production. Indeed, a
number of studies have demonstrated that RAS-driven transformation is
associated with upregulation of antioxidant proteins to neutralize ROS
production. For instance, upregulation of proteins involved in redox
metabolism such as Prx3,4 and selenophosphate synthetase, a rate-
limiting enzyme for synthesis of ROS scavenging selenoproteins such as
GPx and TrxR, has been observed during RAS-driven transformation of
ovarian epithelial cells [130]. More importantly, KRAS has been shown
to directly enhance expression of master antioxidant transcription Nrf2,
that positively regulates expression of critical ROS scavenging enzymes
[131,132]. The increase in antioxidative capacity is also crucial to
mediate RAS-driven transformation and malignant progression. No-
tably, Nrf2 has been shown to confer increased survival and tumor
growth in later stages of malignancy and also chemoresistance in RAS-
driven lung cancer [131,133]. In addition, inhibition of Nrf2 ubiquiti-
nation and degradation via deletion of Sag promotes KRAS-driven skin
papillomagenesis [134]. Numerous reports also observed increased
Nrf2 activity in diverse cancer types, lending credence to its importance
in carcinogenesis [135–137]. Apart from compromising major cellular
antioxidant systems, another study showed that loss of Prx1 in
HRASV12-driven hepatocellular carcinoma was sufficient to induce
apoptosis as a result of decreased ERK activation and increased ROS-
induced DNA damage [138]. In another study, deletion of Pim kinase
was shown to reduce SOD2 and GPx4 expression in KRASG12V-trans-
formed MEFs and sensitize towards RAS-induced ROS-dependent cell
death [139].
Nevertheless, as mentioned, a key to maintaining antioxidant
function of ROS scavenging enzymes is the dependence on NADPH,
which is mainly produced by the Pentose Phosphate Pathway (PPP) and
the key rate-limiting enzyme for this anabolic pathway is glucose-6-
phosphate dehydrogenase (G6PD). Alluding to its role in NADPH
synthesis, G6PD has an important role in protecting cells against oxi-
dative stress via NADPH-mediated restoration of GSH activity
[140,141]. Interestingly, mammalian Target of Rapamycin complex 1
(mTORC1), a downstream effector of RAS/PI3K/AKT pathway, was
shown to directly induce expression of G6PD, that is blocked by treat-
ment with the mTOR inhibitor, rapamycin [142]. The direct connection
between RAS signaling and PPP showcases an important antioxidant
property of RAS, potentially during carcinogenesis.
Another feature in RAS-driven transformation is the accumulation
of dysfunctional mitochondria which is a major source of ROS pro-
duction [107,143]. In this regard, removal of dysfunctional mitochon-
dria through autophagy (mitophagy) could be an important mechanism
for ameliorating oxidative stress. Supporting this concept, mitophagy
was shown to be an important mechanism for maintaining efficient
oxidative metabolism in KRAS-driven lung cancer through maintenance
of healthy pool of mitochondria, and genetic knockdown of Atg5 and
Atg7 was shown to decrease cell survival associated with increased
number of defective mitochondria and decreased respiration [87].
Corroborating these studies, many RAS-driven cancers often exhibit
high basal levels of autophagy, demonstrating the importance of an
Fig. 3. Duality of RAS in redox-regulation. Mutant RAS has both oxidative and antioxidative functions to maintain ROS levels below lethal threshold. Mutant RAS
drives production of ROS to promote cell proliferation and survival. Mutant RAS, through its downstream effectors have been shown to increase ROS production by
stimulating NOX complex through Rac and also disrupting complex I and III activity of the mitochondrial. Mutant RAS also downregulates antioxidant expression
through inhibition of FoxO3A transcription factor. Mutant RAS maintains sublethal levels of ROS by activating Nrf2 transcription of antioxidant genes. Mutant RAS
also induces autophagy to remove dysfunctional mitochondria that contributes to ROS production. Also, mTORC1, a downstream effector of RAS/PI3K/AKT signaling
has also been shown to upregulate G6PD expression required for synthesis of NADPH, an important cofactor in the reduction of redox-cycling enzymes such as GSH
and Trx.
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intact autophagic mechanism during RAS-driven carcinogenesis
[129,144,145]. Interestingly, oncogenic KRAS signaling also promotes
mitochondrial fragmentation, a pre-requisite to mitophagy initiation,
through ERK2-mediated phosphorylation of dynamin-related protein 1
(DRP1) at serine 616 and deletion of DRP1 has been associated with
impaired proliferative capacity of KRAS-driven tumors [146,147]. It is
plausible that KRAS-induced mitochondrial morphology changes could
also play an important role in facilitating the removal of damaged
mitochondria and prevent excessive accumulation of ROS during
transformation. Hence, the involvement of mitochondrial dynamics in
RAS-driven carcinogenesis and its interplay with ROS warrants further
investigation.
Taken together, these studies demonstrate strongly the duality of
RAS oncogene in redox regulation through concurrent oncogenic sti-
mulation of ROS production and increasing antioxidant capacity to
ensure that ROS levels are kept within pro-carcinogenic levels while
avoiding the lethal threshold (Figs. 2 and 3). However, in light of the
conflicting reports, it would be interesting to investigate the circum-
stances and cellular context wherein RAS adopts a pro or anti-oxidant
role. Understanding the plasticity of RAS in redox-regulation will help
us develop more effective therapeutic strategies against RAS-driven
tumors.
6.3. Redox-based strategies against RAS-driven cancers
Given the incidence of RAS mutations in cancer and its involvement
in mediating acquisition of oncogenic hallmarks, it is unsurprising that
direct inhibition of RAS is an important and attractive therapeutic
strategy against RAS-driven tumors. However, a therapeutic grip on
RAS oncogene remains challenging. Nevertheless, there has been some
success in understanding the structure of RAS protein and how it can be
drugged [148–150]. However, the therapeutic efficacy remains to be
established. As a result, the bulk of research efforts are aimed at de-
signing therapeutic strategies targeting upstream and/or downstream
effectors of RAS signaling [151–154]. Despite the initial successes of
these therapies, their durability in the clinic is ultimately compromised
by multiple cross-talk, negative feedback and redundancies that exists
within the complex RAS signaling network, leaving an open area for
development of novel therapies [155–159].
Based on the studies presented, the apparent reliance of RAS-driven
tumors on ROS to sustain its tumorigenic needs presents itself as a
targetable vulnerability to be exploited for therapeutic management.
One possible strategy to target RAS-driven tumors will be to reduce its
pro-proliferative and survival capacity through reducing intracellular
ROS levels (Fig. 2). In support of this concept, one study showed that
treatment of KRAS-driven pancreatic cancer cells with antioxidant, vi-
tamin E evokes an apoptotic response through transcription factor EGR-
1-dependent upregulation of pro-apoptotic BAX [160]. However,
whether or not ROS downregulation was involved in BAX upregulation
was not reported in the study. A more direct strategy proving the via-
bility of this strategy was demonstrated in another study where in-
hibition of NOX4 by flavoprotein inhibitor, diphenyleneiodonium
(DPI), inhibited O2•- production and triggered apoptosis in KRAS-driven
PANC-1 pancreatic cancer cells [161]. More specifically, reduction of
O2•- downregulated phosphorylation/activation of AKT and relieved its
inactivating activity on apoptosis signal-regulating kinase 1 (ASK1),
triggering cell death [161]. Similarly, anti-diabetic drug, metformin,
was also shown to selectively target KRAS-driven pancreatic cancer
cells, PANC-1 and Mia PaCa, by downregulating NOX2 and NOX4 levels
while upregulating SOD2 levels, resulting in overall decreased cell
survival associated with decreased intracellular ROS levels [28].
The reliance of RAS-driven tumors on increased intracellular ROS
production, by the same token, also makes them inherently vulnerable
to further increases in oxidative stress. Therefore, a viable strategy to
target RAS-driven cancers by inducing massive ROS production to reach
lethal levels in these cells [162,163] (Fig. 2). To that end, Shaw et al.
has screened over 50,000 compounds and discovered a class of com-
pounds which selectively targets KRAS mutant cells [164]. Among
which, the most potent member, lanperisone, induces ferrotopsis
through an increase in intracellular ROS levels, that was dependent on
MAPK activation [164]. In another chemical library screen aimed at
identifying new compounds targeting EGFR and KRAS-driven lung
cancer, identified novel compound LCS-1 showed promising activity
against KRAS and EGFR-driven lung cancer cell lines through decreases
in PI3K/AKT and MAPK signaling [165]. Interestingly, a follow-up
study identified SOD1 as a likely target of LCS-1 and silencing of SOD1
conferred increased sensitivity of lung cancer cells towards LCS-1,
possibly owing to further increases in ROS levels due to additive SOD1
loss [166].
Another dietary supplement, ascorbate (vitamin C), was also shown
to selectively target colorectal cancer cells expressing BRAF or KRAS
mutations in which GLUT1 expression is increased [167]. Interestingly,
the observed effect involved the uptake of dehydroascorbate (DHA),
oxidized vitamin C, via glucose transporter GLUT1, which subsequently
exhaust antioxidant GSH levels via its own reduction to ascorbate
[167]. Due to depletion of GSH levels, intracellular ROS increases and
subsequently inactivates glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)-in KRAS or BRAF-driven glycolytic addicted cells, resulting in
energetic crisis and cell death [167]. Consistent with this finding, an
earlier study also demonstrated the anti-tumor effects of ascorbate in
KRAS-driven pancreatic cancer cells was due to an increase in ROS
production [168]. Interestingly, overexpression of GLUT1 transporter
in wild-type cells alone did not increase its susceptibility towards as-
corbate treatment, suggesting that the toxic effects of ascorbate towards
mutant KRAS-expressing cells requires coupling to additional factors
unique to KRAS-driven tumors. One metabolic liability that may render
KRAS-mutant expressing cells susceptible towards ascorbate is its re-
liance on ROS to promote cell proliferation and tumorigenesis [106].
Thus, the toxic effect of ascorbate is likely due to the synthetic lethal
combination created by high rates of ROS production and increased
GLUT1 expression in mutant KRAS-expressing cells.
Along similar lines, we recently unraveled a novel mechanism of
drug-induced mutant KRAS-mediated increase in oxidative stress with
potential therapeutic implications in RAS-driven cancers. The small
molecule (C1) triggered hyperactivation of KRAS in cells expressing
mutant KRAS resulting in AKT-dependent ROS production and execu-
tion of cell death [76]. In addition, cell death induced by C1 displayed
features of apoptosis and autophagy mediated by ROS-dependent acti-
vation of ERK and JNK [12]. Remarkably, similar increase in RAS sig-
naling as a result of mutant and wild-type KRAS heterodimer disruption
also increased sensitivity of lung cancer cells towards MEK inhibition
[169]. It would be interesting to investigate if this increase in sensitivity
is also due to the pro-oxidant effects of RAS signaling which could open
up new avenues for redox-based therapies in treating RAS-driven can-
cers. Taken together, these studies provide a proof- of-concept for de-
veloping ROS-inducing strategies in targeting RAS-driven cancers.
Despite the promising laboratory findings for redox-based approach
towards treating oncogenic KRAS-driven cancers, clinical trials invol-
ving use of redox-active compounds are met with limited success. One
limitation of the use of redox-active dietary supplements such as vita-
mins in treatment of cancer is its oral bioavailability. Early double-blind
placebo-controlled clinical studies of vitamin C in patients with ad-
vanced cancer showed no significant therapeutic benefits when ad-
ministered orally at 10 g per day [170,171]. Another study showed that
despite high dosage of vitamin C, plasma concentration rarely exceeds
200 μM when administered orally due to limited absorption and drug
clearance. As a result, the maximum dose achievable through oral ad-
ministration is well below the effective dose used in in vitro studies
[167]. By contrast, plasma concentration of vitamin C can reach as high
as 15mM when administered intravenously [172]. A recent pilot phase
1/2a clinical studies using combination therapy of intravenous vitamin
C with chemotherapeutics carboplatin and paclitaxel in patients with
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ovarian cancer showed an improved overall survival and median time
of 8.75 months longer disease progression/relapse in vitamin C/car-
boplatin/paclitaxel-treated patients compared to patients receiving
only standard carboplatin/paclitaxel therapy [173]. However, the dif-
ference between two groups of patients was not statically significant
and the efficacy of vitamin C in cancer therapy still warrants further
clinical investigation. Intravenous administration of vitamin E in com-
bination with chemotherapeutics was also studied clinically but no
therapeutic benefits has been observed [174]. Another limitation and
drawback of vitamin C and E in cancer therapy may also be attributed
to its short biological half-life [175,176]. Hence, use of vitamin in
cancer therapy would be impractical as patients would need to be dosed
with high concentrations of vitamins very frequently. Moreover, several
studies revealed pro-oxidant activity in vitamins, contrary to their
presumed antioxidative roles [167,177]. Thus, it would be important to
understand which role would vitamins adopt in vivo and at the tumor
site.
As mentioned, NOX enzymes are also potential targets for ROS-
modulating strategies and inhibition of NOX enzymes has proven ef-
fective against several cancer cell lines [28,119]. Among which, NOX1
and NOX4 has been implicated in RAS-driven carcinogenesis
[30,119,123,161]. NOX1 is abundantly expressed in colon epithelial
cells and appears to play an important role in mucosal wound repair
after inflammation and loss of NOX1 function has been associated with
inflammatory bowel disease [178–180]. Expression of NOX4, on the
other hand, is far more ubiquitous than NOX1, and its diverse function
has recently been reviewed in [181]. Given the importance NOX en-
zymes in physiological functions, inhibition of NOX during cancer
therapy in patients may have severe implications and calls for cautious
optimism.
Lastly, given the complexity of RAS oncogene in redox-regulation, it
is conceivable that RAS-driven tumors may exhibit redox-heterogeneity
across different cell types and stages of carcinogenesis, warranting for
personalized redox-profiling of tumors in any given patient to identify
potential hormetic thresholds. Only then, we would be able to effec-
tively target RAS-driven tumors through manipulation of ROS levels
using drug or combinational therapy (Table 1).
7. Concluding remarks
The treatment of RAS-driven cancers has been therapeutically
challenging due to the complexity and diversity of RAS signaling
readouts. However, an interesting aspect with potential therapeutic
implications is the intricate interplay between RAS networks and cel-
lular redox status. Observations supporting bi-directional signaling
(RAS-ROS-RAS) argue in favor of an amplification loop that on the one
hand provides a permissive environment for transformation, survival
and carcinogenesis, yet on the other hand presents as a vulnerability
worth exploiting for the therapeutic management of RAS driven ma-
lignancies. These observations support a Redox Rheostat function for
RAS. It is worth noting that the contribution of ROS towards cell fate
may be governed by cell-specificity and stages of carcinogenesis, and
therefore for redox-based therapies to be effective, the functional
biology of RAS from the standpoint of redox status in specific cancer
cell types and stages have to be clearly established. Furthermore, is
there a propensity for RAS to switch from an anti-oxidant role to a pro-
oxidant role in response to extrinsic or intrinsic stimuli? If so, what
mechanisms confer the plasticity of RAS in redox-regulation?
Understanding these phenomena would be critical for the design and
development of novel redox-based approaches for the efficient execu-
tion of RAS driven cancers.
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